Skip to main content
Log in

New understanding of hepatobiliary MRI

  • Clinical Outlook
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

Magnetic resonance imaging following injection of hepatobiliary contrast agents improves the detection of hepatocellular carcinomas when contrast agent accumulations in tumours and the surrounding pathological liver differ. However, tissue accumulation is poorly investigated, and this Clinical Outlook article highlights experimental data to understand better contrast agent accumulation in human pathological livers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: Hepatobiliary MRI of hepatocellular carcinomas and the surrounding tissue.

References

  1. Vilgrain, V., Van Beers, B. E. & Pastor, C. M. Insights into the diagnosis of hepatocellular carcinomas with hepatobiliary MRI. J. Hepatol. 64, 708–716 (2016).

    Article  PubMed  Google Scholar 

  2. Narita, M. et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J. Gastroenterol. 44, 793–798 (2009).

    Article  CAS  PubMed  Google Scholar 

  3. Sourbron, S. A tracer-kinetic field theory for medical imaging. IEEE Trans. Med. Imaging 33, 935–946 (2014).

    Article  PubMed  Google Scholar 

  4. Pastor, C. M. & Brouwer, K. L. R. New pharmacokinetic parameters of imaging substrates quantified from rat liver compartments. Drug Metab. Dispos. 50, 58–64 (2022).

    Article  CAS  PubMed  Google Scholar 

  5. Pastor, C. M. & Vilgrain, V. Steatosis alters the activity of hepatocyte membrane transporters in obese rats. Cells 10, 2733 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Taniguchi, T. et al. Interindividual diversity in expression of organic anion uptake transporters in normal and cirrhotic human liver. Hepatol. Commun. 4, 739–752 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Vildhede, A., Kimoto, E., Pelis, R. M., Rodrigues, A. D. & Varma, M. V. S. Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease. Clin. Pharmacol. Ther. 107, 1128–1137 (2020).

    Article  CAS  PubMed  Google Scholar 

  8. Hardwick, R. N., Fisher, C. D., Canet, M. J., Scheffer, G. L. & Cherrington, N. J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 39, 2395–2402 (2011).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Leporq, B. et al. Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MRI in patients with chronic liver disease. Clin. Sci. 132, 813–824 (2018).

    Article  CAS  Google Scholar 

  10. Bastati, N. et al. Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. Radiology 271, 739–747 (2014).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Catherine M. Pastor.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Related links

MASH: https://www.aasld.org/new-masld-nomenclature

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pastor, C.M., Vilgrain, V. New understanding of hepatobiliary MRI. Nat Rev Gastroenterol Hepatol (2024). https://doi.org/10.1038/s41575-024-00926-z

Download citation

  • Published:

  • DOI: https://doi.org/10.1038/s41575-024-00926-z

  • Springer Nature Limited

Navigation